Verrica Pharmaceuticals (VRCA) Corporate presentation summary

Commercial performance and product highlights

• YCANTH is the first FDA-approved treatment for molluscum contagiosum in patients aged 2 and older, with 2025 product revenue of $15.3M, up 130% year-over-year, and Q2 2026 revenue of $5.1M.

• YCANTH was approved in Japan in September 2025 and launched by Torii Pharmaceutical in February 2026.

• The company reduced SG&A expenses by approximately 40% in 2025 while expanding commercial reach.

• YCANTH has broad reimbursement coverage, streamlined provider experience, and a co-pay assistance program.

• Access to non-dilutive growth capital includes a $27.5M credit facility announced in August 2026.

Pipeline and clinical development

• YCANTH is in a global Phase 3 program for common warts, with Torii funding the first $40M of trial costs and topline data expected mid-2027.

• VP-315, an innovative immunotherapy for basal cell carcinoma (BCC), showed a 97% objective response rate and 51% complete histological clearance in Phase 2.

• FDA alignment achieved for Phase 3 pivotal studies of VP-315 in BCC, with two 100-patient placebo-controlled trials planned.

• Expansion opportunities exist for VP-315 into other skin cancers, including squamous cell carcinoma.

• The pipeline is supported by strong intellectual property protection, with U.S. IP for YCANTH expiring between 2036 and 2041 and for VP-315 between 2032 and 2045.

Clinical data and efficacy

• Phase 3 studies for YCANTH in molluscum showed statistically significant complete clearance rates and over 30% lesion count reduction after one dose.

• Phase 2 data for YCANTH in common warts demonstrated over 50% full clearance after four treatments, with a favorable safety profile.

• VP-315 Phase 2 in BCC demonstrated no treatment-related serious adverse events, 86% overall tumor size reduction, and evidence of an abscopal effect.

• VP-315’s dual mechanism involves direct tumor cell killing and immune activation, supported by leading cancer research institutions.